Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Dimerix Limited
  6. Summary
    DXB   AU000000DXB7

DIMERIX LIMITED

(DXB)
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Australian Stock Exchange
01/19/2022 01/20/2022 01/21/2022 01/24/2022 01/25/2022 Date
0.26(c) 0.26(c) 0.255(c) 0.245(c) 0.235(c) Last
190 513 561 079 927 701 566 005 437 815 Volume
-3.70% 0.00% -1.92% -3.92% -4.08% Change
More quotes
Estimated financial data (e)
Sales 2020 2,34 M 1,68 M 1,68 M
Net income 2020 -4,49 M -3,22 M -3,22 M
Net cash position 2020 6,69 M 4,79 M 4,79 M
P/E ratio 2020 -13,4x
Yield 2020 -
Sales 2021 4,44 M 3,18 M 3,18 M
Net income 2021 -6,37 M -4,56 M -4,56 M
Net cash position 2021 0,16 M 0,11 M 0,11 M
P/E ratio 2021 -6,06x
Yield 2021 -
Capitalization 75,4 M 54,0 M 54,0 M
EV / Sales 2020 26,7x
EV / Sales 2021 8,66x
Nbr of Employees -
Free-Float -
More Financials
Company
Dimerix Limited is an Australia-based biopharmaceutical company. The Company is engaged in the development of new therapies in areas with unmet medical need. The Company is developing four product indications: Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19, diabetic kidney disease, and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD), as well as the its... 
More about the company
All news about DIMERIX LIMITED
01/10Dimerix Doses First Patients in Phase 3 Study of COVID-19 Respiratory Complications Dru..
MT
01/10Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India
CI
2021Dimerix Secures Australian Ethics Approval for Phase 3 Study of COVID-19 Drug Candidate..
MT
2021Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study
CI
2021Dimerix Secures Further Grant Funding for COVID-19 Drug Candidate
MT
2021Dimerix Limited Announces It Has Been Awarded Further AUD 100,000 from the Australian G..
CI
2021Dimerix Limited Advises That 662 Patients Have Now Been Recruited into the Feasibility/..
CI
2021DIMERIX : Notification regarding unquoted securities - DXB
PU
2021DIMERIX : Secures Ethics, Regulatory Approval for Phase 3 Kidney Disease Trial in Australi..
MT
2021Dimerix Limited Announces First Approvals Received for Start of Phase 3 FSGS Trial
CI
2021DIMERIX : Expands Phase 3 Study for COVID-19 Drug to Australia; Shares Rise 4%
MT
2021Dimerix Limited Announces Phase 3 DMX-200 Covid-19 Study Expands into Australia
CI
2021DIMERIX : to Raise $3 Million in Oversubscribed Share Purchase Plan
MT
2021DIMERIX : India's Drug Regulator Approves Dimerix's COVID-19 Drug Clinical Study
MT
2021Dimerix Limited Recommends DMX-200 Clinical Study in COVID-19 Patients
CI
More news
News in other languages on DIMERIX LIMITED
01/10Dimerix administre les premiers patients de l'étude de phase 3 du COVID-19, un médicame..
01/10Dimerix annonce l'administration de doses à des patients dans le cadre de l'étude de ph..
2021Dimerix obtient l'approbation éthique australienne pour l'étude de phase 3 du candidat ..
2021Dimerix Limited reçoit l'approbation éthique en Australie pour l'étude de phase 3 Covid..
2021Dimerix obtient l'approbation éthique et réglementaire pour un essai de phase 3 sur les..
More news
Chart DIMERIX LIMITED
Duration : Period :
Dimerix Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DIMERIX LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Nina Webster Chief Executive Officer, MD & Director
Hamish George Chief Financial Officer & Secretary
James Howard Williams Non-Executive Chairman
David Packham Chief Medical Officer
Robert Shepherd Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
DIMERIX LIMITED-4.08%54
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381